<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01657123</url>
  </required_header>
  <id_info>
    <org_study_id>33088</org_study_id>
    <nct_id>NCT01657123</nct_id>
  </id_info>
  <brief_title>Exercise Capacity and Recovery in Addison's Disease</brief_title>
  <official_title>Effect of Hydrocortisone Stress Dose on Exercise Capacity and Post-exercise Recovery in Patients With Addison's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exposure to stress alters the activity of the adrenomedullary, adrenocortical and sympathetic
      nervous system, depending on the type and intensity of the stressor. Physical exercise
      represents a stress condition influencing many systems in the body. Given a workload of at
      least 70-85% of Vo2max, exercise is a potent stimulus of the hypothalamic-pituitary-adrenal
      (HPA)-axis. The increased endogenous cortisol secretion results in important metabolic and
      cardiovascular effects to maintain cellular and organ homeostasis. Patients with Addison's
      disease are not able to meet the increased demand of adrenal steroids in case of physical
      exercise, which may result in an impaired exercise capacity and a prolonged post-exercise
      recovery. We hypothesize that a hydrocortisone stress dose increases exercise capacity and
      improves post-exercise recovery in patients with Addison's disease.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>exercise capacity</measure>
    <time_frame>140 minutes</time_frame>
    <description>power in Watt and duration in minutes</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Addison's Disease</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>hydrocortisone stress dosage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ergometry</intervention_name>
    <description>ergometry measurements</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ergometry</intervention_name>
    <description>Ergometry measurements</description>
    <arm_group_label>hydrocortisone stress dosage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Addison's disease

          -  18-50 years

          -  stable glucocortiocid replacement therapy

        Exclusion Criteria:

          -  Presence of intercurrent (acute) infectious disease

          -  Mental impairment (major depressive, anxiety, panic, adjustment, bipolar, psychotic,
             posttraumatic or borderline personality disorder)

          -  Presence of the following chronic diseases: diabetes mellitus, chronic obstructive
             pulmonary disease, renal failure, chronic anaemia, malignancy, rheumatoid arthritis

          -  Presence of the following cardiovascular conditions: unstable angina pectoris, history
             of myocardial infarction, uncontrolled cardiac arrhythmias causing symptoms or
             hemodynamic compromise, symptomatic (severe) aortic stenosis, uncontrolled symptomatic
             heart failure, acute myocarditis or pericarditis, left main coronary stenosis,
             moderate stenotic valvular heart disease, tachyarrhythmias or bradyarrhythmias,
             hypertrophic cardiomyopathy and other forms of outflow tract obstruction, high-degree
             atrioventricular block

          -  History of pulmonary embolus or pulmonary infarction

          -  Known aortic aneurysm

          -  Severe hypertension (&gt;170/100 mm Hg)

          -  Medication that affects cardiovascular function (beta-blocker, calcium antagonist,
             ACE-inhibitors, aldosterone-antagonists)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lisanne Smans, drs</last_name>
    <phone>0031616796646</phone>
    <email>l.c.c.j.smans@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pierre Zelissen, dr</last_name>
    <phone>0031887550686</phone>
    <email>p.m.j.zelissen@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisanne Smans, drs</last_name>
      <phone>0031616796646</phone>
      <email>l.c.c.j.smans@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Pierre Zelissen, dr</last_name>
      <phone>0031887550686</phone>
      <email>p.m.j.zelissen@umcutrecht.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2012</study_first_submitted>
  <study_first_submitted_qc>August 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2012</study_first_posted>
  <last_update_submitted>August 2, 2012</last_update_submitted>
  <last_update_submitted_qc>August 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Smans</investigator_full_name>
    <investigator_title>drs</investigator_title>
  </responsible_party>
  <keyword>exercise capacity</keyword>
  <keyword>Addison's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Addison Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

